William D. Schwieterman

Managing Director, Regulatory at Perceptive Advisors LLC

William D. Schwieterman

William D. Schwieterman

Managing Director, Regulatory at Perceptive Advisors LLC

Overview
Career Highlights

Neumedics, Inc.
Oncotelic Therapeutics, Inc.

RelSci Relationships

2069

Number of Boards

3

Birthday

1958

Age

63

Number of Awards

1

Relationships
RelSci Relationships are individuals William D. Schwieterman likely has professional access to. A relationship does not necessarily indicate a personal connection.

Chief Business & Strategy Officer at Athenex, Inc.

Relationship likelihood: Strong

Chief Financial Officer at Flexion Therapeutics, Inc.

Relationship likelihood: Strong

Chairman, President & Chief Executive Officer at Oncotelic Therapeutics, Inc.

Relationship likelihood: Strong

Chief Investment Officer at Perceptive Advisors LLC

Relationship likelihood: Strong

Managing Director at Perceptive Advisors LLC

Relationship likelihood: Strong

General Partner at Cultivation Capital LLC

Relationship likelihood: Strong

Partner at Wyrick Robbins Yates & Ponton LLP

Relationship likelihood: Strong

President & Chief Executive Officer at Harpoon Therapeutics, Inc.

Relationship likelihood: Strong

Former Senior Vice President & Director-Business Development at GlaxoSmithKline Plc

Relationship likelihood: Strong

Executive Medical Director, Global Oncology at Clinipace, Inc.

Relationship likelihood: Strong

Paths to William D. Schwieterman
Potential Connections via
Relationship Science
You
William D. Schwieterman
Managing Director, Regulatory at Perceptive Advisors LLC
Career History
Chief-Medicine, Immunology & Infectious Disease
Prior

The Food and Drug Administration (FDA or USFDA) is an agency of the United States Department of Health and Human Services, one of the United States federal executive departments. The FDA is responsible for protecting and promoting public health through the regulation and supervision of food safety, tobacco products, dietary supplements, prescription and over-the-counter pharmaceutical drugs (medications), vaccines, biopharmaceuticals, blood transfusions, medical devices, electromagnetic radiation emitting devices (ERED), and veterinary products. The FDA also enforces other laws, notably Section 361 of the Public Health Service Act and associated regulations, many of which are not directly related to food or drugs. These include sanitation requirements on interstate travel and control of disease on products ranging from certain household pets to sperm donation for assisted reproduction. The FDA is led by the Commissioner of Food and Drugs, appointed by the President with the advice and consent of the Senate. The Commissioner reports to the Secretary of Health and Human Services. The 21st and current Commissioner is Dr. Margaret A. Hamburg. She has served as Commissioner since May 2009. The FDA has its headquarters in unincorporated White Oak, Maryland. The agency also has 223 field offices and 13 laboratories located throughout the 50 states, the United States Virgin Islands, and Puerto Rico. In 2008, the FDA started opening offices in foreign countries, including China, India, Costa Rica, Chile, Belgium, and the United Kingdom. In June 1906, President Theodore Roosevelt signed into law the Food and Drug Act, also known as the "Wiley Act" after its chief advocate Dr. Harvey Washington Wiley who riveted the country's and eventually congress's attention with public hygiene demonstrations. This act was the basis for the modern USFDA, being originally given the name of the Food, Drug, and Insecticide organization. The name eventually was shortened to the Food and Drug Administration (FDA) a few years later.

Chief Medical Officer
2009 - 2014

Chelsea Therapeutics International Ltd. acquires, develops and commercializes innovative products for the treatment of a variety of human diseases. The company was founded by Simon C. Pedder on June 17, 2005 and is headquartered in Charlotte, NC.

Chief Executive Officer & President
2015 - 2020

Oncotelic Therapeutics, Inc. is a biopharmaceutical company. It engages in developing anti-vascular therapeutics for patients with cancer and sight-threatening eye diseases. The firm operates through the following segments: PointR, Mateon/Oxigene and Oncotelic. The PointR segment develops vision grid/cluster computing/AI to support drug development. The Mateon/Oxigene segment develops Vascular Disrupting Agent (CA4P and Oxi4503). The Oncotelic segment develops OT-101, an antisense against TGF-beta- for the treatment of cancers. Oncotelic Therapeutics was founded in 1988 and is headquartered in Agoura Hills, CA.

Boards & Committees
Chairman, Board of Directors
2007 - 2020
Member, Board of Directors
Tenure Unconfirmed
Director
Tenure Unconfirmed
Transactions
Details Hidden

Oncotelic Therapeutics, Inc. raised money in a private placement transaction

Awards & Honors
Board Certified Internist
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by William D. Schwieterman. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of William D. Schwieterman's profile does not indicate a business or promotional relationship of any kind between RelSci and William D. Schwieterman.